Figure 2.

A bar chart displaying peak plasma concentration (C_max)/effective concentration 90% (EC₉₀) ratio for compounds studied for in vitro antiviral activity against severe acute respiratory syndrome‐coronavirus 2 for which data were available to recalculate an EC₉₀. Drugs with a ratio below 1 were deemed not to provide plasma concentrations at their approved doses to exert sufficient systemic antiviral activity. Those drugs with a ratio above 1 (shown in orange) were deemed to have potential to provide plasma concentrations sufficient to exert at least some antiviral activity for at least some of their dosing interval at their approved dose. Drugs shown in green were predicted to exceed plasma concentrations over their EC₉₀ by more than twofold.